WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.:
- Do you own shares of SciClone Pharmaceuticals, Inc. (NASDAQ GS: SCLN)?
- Did you purchase any of your shares prior to June 8, 2017?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ GS: SCLN) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by a consortium consisting of entities affiliated with GL Capital Management GP Limited ("GL Capital"), Bank of China Group Investment Limited ("BOCGI"), CDH Investments, Ascendent Capital Partners and Boying (collectively, the "Buyer Consortium") in a transaction valued at approximately $605 million. Under the terms of the agreement, shareholders of SciClone will receive $11.18 in cash for each share of SciClone common stock.
Click here to learn more: http://rigrodskylong.com/investigations/sciclone-pharmaceuticals-inc-scln.
If you own common stock of SciClone and purchased any shares before June 8, 2017, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at firstname.lastname@example.org; or at: http://rigrodskylong.com/investigations/sciclone-pharmaceuticals-inc-scln.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.